C-donepezil PET' by Gjerløff et al. (10.1093/brain/ awu369) .
The possibility of assessing disease progression in Parkinson's disease was revolutionized by the ability to image dopamine synthesis in vivo, first described by Garnett and colleagues more than 30 years ago (Garnett et al., 1983) . Since that landmark paper, there have been hundreds of publications presenting the results of molecular imaging using either SPECT or PET tracers for the synthesis, synaptic packaging and/or reuptake of dopamine. While the relationship between changes in dopamine function assessed by these techniques and clinical deterioration is imperfect and may be confounded by compensatory changes and the effects of medications, it is nonetheless possible to obtain an independent measure of disease progression and indeed to detect pre-motor dopaminergic dysfunction in subjects at high risk of future Parkinson's disease (Nandhagopal et al., 2008; Iranzo et al., 2011) . However, in recent years it has been proposed that changes in the dopamine system (and motor impairment) may not become manifest until relatively late in the disease course. By contrast, the autonomic nervous system shows early involvement; indeed it has been suggested that the deposits of aberrantly folded -synuclein associated with Parkinson's disease may originate in autonomic nerve endings of the gastrointestinal tract and be retrogradely transmitted to the caudal brainstem via the vagus nerve (Braak et al., 2003) (Fig. 1) . Several studies have used imaging to demonstrate cardiac sympathetic denervation in early Parkinson's disease and even in subjects with REM sleep behaviour disorder (Kashihara et al., 2010), but until now, the imaging community has paid little attention to the parasympathetic nervous system. In this issue of Brain, Gjerløff et al. describe the application of 11 C-methoxy-donepezil PET to study the distribution of acetylcholinesterase activity in a semi-quantitative fashion in the periphery, and by implication in the parasympathetic nervous system (Gjerløff et al., 2014) .
Gjerløff et al. report reductions of 11 C-donepezil binding of 35% in the small intestine and 22% in the pancreas of patients with early to moderate Parkinson's disease compared to age-and gender-matched healthy controls. There was no correlation between reductions in 11 C-donepezil binding and disease duration. This may not be surprising if Parkinson's disease starts in the peripheral nervous system and spreads in a caudal to rostral fashion. However, the authors also failed to find a correlation between 11 C-donepezil binding and measures of vagal function such as gastric emptying and severity of constipation, raising questions regarding the relationship between 11 C-donepezil binding and parasympathetic function. It must be noted that contrary to expectations, there was no evidence of delayed gastric emptying in this cohort of patients (indeed the opposite was observed, possibly reflecting the use of levodopa medication). A smaller but significant reduction was seen in myocardial uptake of the tracer, but the basis for this reduction is more difficult to determine, and it did not correlate with measures of heart rate variability.
The protocol described by Gjerløff et al. is technically challenging. Spillover from adjacent structures and peristaltic movement make it difficult to obtain robust measures from the regions of interest, and uptake in the small intestine is patchy. The estimation of distribution volumes requires accounting for the presence of radioactive metabolites. Such measures in arterial plasma are often noisy and subject to considerable error. Furthermore, radiolabelled metabolites may not necessarily be identical in the organs of interest and in arterial plasma. There seems to be no easy way to account for non-specific uptake of the radioligand. The authors have attempted to address these potential pitfalls as best they can and have used standardized uptake values (SUVs) for their comparisons and correlations. The SUV is more easily determined although not quite as readily interpreted from a biological perspective, but SUV measurements correlated reasonably well with distribution volume estimates. There is considerable interindividual variability in the SUVs, particularly in pancreas, and an associated high degree of overlap between the Parkinson's disease and healthy control groups. The kinetic analysis suggested that group differences were related to tracer washout rather than differences in blood flow to the organs of interest, although it should be noted (Table 3 of the article) that the difference in intestinal k2 was not significant (reflecting tracer washout) and there was in fact a modest but non-significant reduction in k1 (reflecting tracer delivery), so this must be regarded as not fully resolved. Whereas Gjerløff et al. have found that 11 Cdonepezil binding data are best fit using a single compartment model, other investigators favour a two-compartment model, at least in brain (Hiraoka et al., 2009) , which would fit better with a specific binding/substrate compartment within the tissue of interest.
Donepezil binds to sigma1 receptors in the brain (Ishikawa et al., 2009 ) and as these receptors are also found in the gut (Harada et al., 1994) , it is possible that the binding described here may not be entirely reflective of acetylcholinesterase activity. Furthermore, as the authors point out, cholinesterase activity is widely accepted as a reasonable but imperfect measure of cholinergic nerve terminal function. The authors have been extremely circumspect in their interpretation of the findings, and recognize the possibility of downregulated cholinesterase activity in preserved but dysfunctional cholinergic parasympathetic nerve terminals. Independent verification of cholinergic nerve terminal loss using a radiolabelled marker for the vesicular acetylcholine transporter would be welcome.
The demonstration by Gjerløff and colleagues of reduced parasympathetic innervation of the intestine and pancreas is interesting but not surprising, given what is already known about Parkinson's disease from studies at autopsy. Alpha-synuclein pathology can also be assessed in vivo by colonic biopsy, although this might be considered more invasive (but also more widely available) than PET imaging. What might be the potential utility of demonstrating peripheral cholinergic denervation in patients with established parkinsonism? Could this approach help differentiate Parkinson's disease (vagal denervation) from atypical parkinsonism such as multiple system atrophy and progressive supranuclear palsy, as has been suggested for cardiac scintigraphy to assess the presence or absence of post-ganglionic sympathetic denervation? Given that the vagus is affected in multiple system atrophy, this seems unlikely, and even the specificity of cardiac scintigraphy has been questioned (Raffel et al., 2006) . Would assessment of gastrointestinal parasympathetic denervation provide an independent biomarker for disease progression? This also seems unlikely, given that the disease may start in the gut, such that the damage is done by the time motor symptoms appear, and given the failure to demonstrate a correlation between disease duration and cholinesterase activity. Is there any use in studying gut cholinergic activity in asymptomatic individuals at high risk of Parkinson's disease, such as those with known pathogenic mutations, hyposmia, or REM behaviour disorder? This may be of limited practical value until neuroprotective therapies are identified, but the demonstration of gastrointestinal vagal denervation prior to imaging evidence of dopamine dysfunction would provide validation of Braak's (Braak et al., 2003) provocative hypothesis.
